BSC 4101
Alternative Names: BSC-4101Latest Information Update: 06 Jul 2023
At a glance
- Originator BiSiChem
- Class Antibodies; Drug conjugates; Immunoconjugates
- Mechanism of Action Undefined mechanism
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
- Available For Licensing Yes
Highest Development Phases
- Research Unspecified
Most Recent Events
- 27 Jun 2023 BSC 4101 is available for licensing as of 27 Jun 2023. https://bisichem.com/default/#about (BiSiChem website, June 2023)
- 27 Jun 2023 Early research in Unspecified in South Korea (Parenteral) before June 2023 (BiSiChem pipeline, June 2023)